Nathalie HeuzÃ©-Vourc'h

List of Publications by Year
in descending order

29 papers	923 citations	471061 17 h-index	476904 29 g-index
31 all docs	31 docs citations	31 times ranked	1141 citing authors

#	Article	IF	Citations
1	Therapeutic antibodies â€“ natural and pathological barriers and strategies to overcome them. , 2022, 233, 108022.		15
2	Pneumocystis Pneumonia: Pitfalls and Hindrances to Establishing a Reliable Animal Model. Journal of Fungi (Basel, Switzerland), 2022, 8, 129.	1.5	3
3	Aggregates Associated with Instability of Antibodies during Aerosolization Induce Adverse Immunological Effects. Pharmaceutics, 2022, 14, 671.	2.0	15
4	Therapeutic Antibodies for the Treatment of Respiratory Tract Infectionsâ€"Current Overview and Perspectives. Vaccines, 2021, 9, 151.	2.1	4
5	Inhaled antibodies: formulations require specific development to overcome instability due to nebulization. Drug Delivery and Translational Research, 2021, 11, 1625-1633.	3.0	27
6	Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States. Pharmaceutics, 2021, 13, 912.	2.0	2
7	Inhaled bacteriophage therapy in a porcine model of pneumonia caused by <scp>Pseudomonas aeruginosa</scp> during mechanical ventilation. British Journal of Pharmacology, 2021, 178, 3829-3842.	2.7	14
8	Pressurized Metered Dose Inhaler Aerosol Delivery Within Nasal High-Flow Circuits: A Bench Study. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2021, 34, 303-310.	0.7	5
9	Controlled Heat and Humidity-Based Treatment for the Reuse of Personal Protective Equipment: A Pragmatic Proof-of-Concept to Address the Mass Shortage of Surgical Masks and N95/FFP2 Respirators and to Prevent the SARS-CoV2 Transmission. Frontiers in Medicine, 2020, 7, 584036.	1.2	12
10	Low-Frequency Intrapulmonary Percussive Ventilation Increases Aerosol Penetration in a 2-Compartment Physical Model of Fibrotic Lung Disease. Frontiers in Bioengineering and Biotechnology, 2020, 8, 1022.	2.0	1
11	Correlation and clinical relevance of animal models for inhaled pharmaceuticals and biopharmaceuticals. Advanced Drug Delivery Reviews, 2020, 167, 148-169.	6.6	19
12	Innovative preclinical models for pulmonary drug delivery research. Expert Opinion on Drug Delivery, 2020, 17, 463-478.	2.4	45
13	Protein stability during nebulization: Mind the collection step!. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 23-34.	2.0	26
14	In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration. Journal of Controlled Release, 2019, 303, 24-33.	4.8	18
15	Inhalation of Immuno-Therapeutics/-Prophylactics to Fight Respiratory Tract Infections: An Appropriate Drug at the Right Place!. Frontiers in Immunology, 2019, 10, 2760.	2.2	28
16	Human kallikrein-related peptidase 12 stimulates endothelial cell migration by remodeling the fibronectin matrix. Scientific Reports, 2018, 8, 6331.	1.6	15
17	Insights on animal models to investigate inhalation therapy: Relevance for biotherapeutics. International Journal of Pharmaceutics, 2018, 536, 116-126.	2.6	34
18	Designing inhaled protein therapeutics for topical lung delivery: what are the next steps?. Expert Opinion on Drug Delivery, 2018, 15, 729-736.	2.4	74

#	Article	IF	Citations
19	Inhaled phage therapy: a promising and challenging approach to treat bacterial respiratory infections. Expert Opinion on Drug Delivery, 2017, 14, 959-972.	2.4	37
20	Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin. Journal of Controlled Release, 2016, 234, 21-32.	4.8	57
21	Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opinion on Drug Delivery, 2015, 12, 1027-1039.	2.4	105
22	Aerosol Route to Administer Teicoplanin in Mechanical Ventilation: In Vitro Study, Lung Deposition and Pharmacokinetic Analyses in Pigs. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015, 28, 290-298.	0.7	14
23	Effect of formulation on the stability and aerosol performance of a nebulized antibody. MAbs, 2014, 6, 1347-1355.	2.6	74
24	Angiogenesis stimulated by human kallikreinâ€related peptidase 12 actingviaa plateletâ€derived growth factor Bâ€dependent paracrine pathway. FASEB Journal, 2014, 28, 740-751.	0.2	33
25	VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. MAbs, 2014, 6, 1638-1648.	2.6	30
26	Pro-angiogenic effect of human kallikrein-related peptidase 12 (KLK12) in lung endothelial cells does not depend on kinin-mediated activation of B2 receptor. Biological Chemistry, 2013, 394, 385-391.	1.2	15
27	The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors. Pharmaceutical Research, 2011, 28, 2147-2156.	1.7	64
28	Kallikrein-related Peptidase 12 Hydrolyzes Matricellular Proteins of the CCN Family and Modifies Interactions of CCN1 and CCN5 with Growth Factors. Journal of Biological Chemistry, 2011, 286, 25505-25518.	1.6	52
29	Aerodynamical, Immunological and Pharmacological Properties of the Anticancer Antibody Cetuximab Following Nebulization. Pharmaceutical Research, 2008, 25, 1318-1326.	1.7	51